[Opinion] Should the 90% CI for GMR be required to encompass 1 [RSABE / ABEL]

posted by jag009  – NJ, 2018-03-28 23:25 (2013 d 20:25 ago) – Posting: # 18606
Views: 9,543

Hi,

❝ My motivation for the original question: it is conceivable that a one could find T(100mg) and R(112mg) BE with a large enough sample. It is also conceivable that one may find 125mg BE with 112mg. This would cause substantial risk of harm. I thought that perhaps imposing the CI through GMR of 1 limit may prevent this from happening.


I think your clarification above is even more confusing. Your example "T(100mg) vs R(112mg) is bioequivalent with a large enough sample size". Are you trying to say that a large enough sample size can force a 100 mg product and a 112 mg product to become bioequivalent because the BE window has a ± 20% around 100%? Please don't forget that there is a criteria on T/R total assay/potency to be within 5%. Your 110mg and 112 mg has >5% potency and that alone invalidates your example.

John

Complete thread:

UA Flag
Activity
 Admin contact
22,764 posts in 4,776 threads, 1,628 registered users;
13 visitors (0 registered, 13 guests [including 5 identified bots]).
Forum time: 19:51 CEST (Europe/Vienna)

The object of statistics is information.
The objective of statistics is the understanding of information
contained in data.    Irwin and Marylees Miller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5